- Home
- IZM vs NRXP Comparison
IZM vs NRXP Comparison
Compare IZM & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IZM
- NRXP
- Stock Information
- Founded
- IZM 2011
- NRXP 2015
- Country
- IZM China
- NRXP United States
- Employees
- IZM N/A
- NRXP N/A
- Industry
- IZM Consumer Electronics/Video Chains
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- IZM Consumer Discretionary
- NRXP Health Care
- Exchange
- IZM Nasdaq
- NRXP Nasdaq
- Market Cap
- IZM 28.7M
- NRXP 32.6M
- IPO Year
- IZM 2023
- NRXP N/A
- Fundamental
- Price
- IZM $2.62
- NRXP $3.40
- Analyst Decision
- IZM
- NRXP Strong Buy
- Analyst Count
- IZM 0
- NRXP 4
- Target Price
- IZM N/A
- NRXP $28.50
- AVG Volume (30 Days)
- IZM 23.7K
- NRXP 284.1K
- Earning Date
- IZM 07-25-2025
- NRXP 08-13-2025
- Dividend Yield
- IZM N/A
- NRXP N/A
- EPS Growth
- IZM N/A
- NRXP N/A
- EPS
- IZM N/A
- NRXP N/A
- Revenue
- IZM $180,553,977.00
- NRXP N/A
- Revenue This Year
- IZM N/A
- NRXP N/A
- Revenue Next Year
- IZM N/A
- NRXP N/A
- P/E Ratio
- IZM N/A
- NRXP N/A
- Revenue Growth
- IZM N/A
- NRXP N/A
- 52 Week Low
- IZM $1.18
- NRXP $1.10
- 52 Week High
- IZM $3.19
- NRXP $6.01
- Technical
- Relative Strength Index (RSI)
- IZM 61.84
- NRXP 59.13
- Support Level
- IZM $2.50
- NRXP $2.90
- Resistance Level
- IZM $2.74
- NRXP $3.53
- Average True Range (ATR)
- IZM 0.09
- NRXP 0.20
- MACD
- IZM 0.01
- NRXP -0.03
- Stochastic Oscillator
- IZM 78.95
- NRXP 79.37
About IZM ICZOOM Group Inc.
ICZOOM Group Inc is engaged in the sale of electronic component products to customers in China. These products are used by small and medium-sized enterprises (SMEs) in the consumer electronic industry, Internet of Things (IoT), automotive electronics, and industrial control segment. In addition to the sales of electronic component products, also provides services to customers such as temporary warehousing, logistic and shipping, and customs clearance and charges them additional service commission fees. The company earns maximum revenue from sale of electronic components.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.